AIM ImmunoTech
AIMAIM · Stock Price
Historical price data
Overview
AIM ImmunoTech is a US-based public company focused on researching and developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19. Its core asset is Ampligen® (rintatolimod), a clinical-stage immuno-modulator with approved use in Argentina for severe Chronic Fatigue Syndrome and active Phase 2 trials in pancreatic cancer. The company's strategy hinges on the broad-spectrum activity of this single platform to create value across multiple, disparate indications, though it remains pre-revenue and faces significant development and financial risks.
Technology Platform
Centered on Ampligen® (rintatolimod), a synthetic double-stranded RNA (dsRNA) molecule that acts as a Toll-like receptor 3 (TLR3) agonist to stimulate the innate immune system, providing broad-spectrum anti-viral and anti-tumor activity.
Pipeline
14| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Ampligen | Chronic Fatigue Syndrome | Phase 3 | |
| Alferon LDO | Severe Acute Respiratory Syndrome | Phase 2 | |
| poly I-poly C12U | HIV Seropositivity | Phase 2 | |
| EC Aspirin + Recombinant Interferon Alfa-2b + Rintatolimod | Prostate Adenocarcinoma | Phase 2 | |
| poly I-poly C12U | HIV Seropositivity | Phase 2 |
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Faces intense competition in pancreatic cancer from established chemotherapies, targeted agents, and novel immuno-oncology combinations. In ME/CFS/Long COVID, the landscape is less crowded but includes repurposed drugs and novel mechanisms from other biotechs. Ampligen's differentiation lies in its unique TLR3 mechanism and extensive, if mixed, clinical history.